By Prof Desiree Silva, Director of Research, Joondalup
Childhood asthma accounts for 43% of asthma hospitalisations and remains the leading cause of total disease burden in children aged between one and nine years.
An estimated $1.192 billion was spent on the treatment and management of asthma in 2022 and 2023. But what if we could pinpoint the children who are on the genetic pathway to develop asthma, before the wheeze and hospital visits, and intervene early enough to change that trajectory?
This is the ambitious goal of AERIAL, a sub-project within ORIGINS, Australia's largest longitudinal birth...
Childhood asthma accounts for 43% of asthma hospitalisations and remains the leading cause of total disease burden in children aged between one and nine years.
An estimated $1.192 billion was spent on the treatment and management of asthma in 2022 and 2023. But what if we could pinpoint the children who are on the genetic pathway to develop asthma, before the wheeze and hospital visits, and intervene early enough to change that trajectory?
This is the ambitious goal of AERIAL, a sub-project within ORIGINS, Australia's largest longitudinal birth...
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.